Ther 08
Alternative Names: Ther-08Latest Information Update: 29 Nov 2025
At a glance
- Originator Theravia
- Class Antiallergics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Hypersensitivity
Most Recent Events
- 21 Jul 2025 Ther 08 is available for licensing as of 21 Jul 2025. https://www.theravia.com/partnering
- 21 Jul 2025 Phase-I clinical trials in Hypersensitivity (unspecified route), before July 2025 (Theravia pipeline, July 2025)